Lauren has more than 25 years’ experience, including extensive corporate experience as a senior executive and general counsel. The primary focus of Lauren’s legal practice is to develop and implement global IP strategies with an emphasis on obtaining strong patent protection, assessing third party patent estates, and resolving potential issues related to enforceability, patentability, and validity. Lauren has extensive experience with approved drug products, including KEVEYIS®, CAMBIA®, INGREZZA®, ONGENTYS®, ORLISSA®, DUEXIS®, RAYOS®, VIMOVO®, PENNSAID® 2%, RAVICTI®, KRYSTEXXA®, ACTIMMUNE®, PROCYSBI®, and BELVIQ®, and many drugs prior to FDA approval, including roxadustat, etrasimod, ralinepag, temanogrel, tirasemtiv, and omecamtiv mecarbil. In addition, Lauren has procured U.S. and foreign patents with an emphasis on small molecule pharmaceutical chemistry, prepared Orange Book listability, patentability, validity, and infringement analyses and FDA patent listing forms, and participated in >10 inter partes review proceedings, including drafting patent owner preliminary responses and patent owner responses, resulting in 6 denials of institution, 4 positive final written decisions, and 1 loss. Lauren has also been a lecturer on practical aspects of chemical and pharmaceutical U.S. patent practices, including co-originator and instructor for the Patent Resources Group courses on Orange Book listing and strategies for inter partes review in the pharma context.

EDUCATION

Lauren earned her J.D. degree from Stanford Law School (1992) and her Ph.D. in organic chemistry from Yale University (1988). She received her B.A. degree in chemistry from DePauw University (summa cum laude, 1982).

LICENSES

• Licensed to practice before the United States Patent and Trademark Office

• Licensed to practice law in the State of California